Location: Anywhere in the U.S. (Remote Position) – about 10-20% of travel once pandemic restrictions are resolved.
Xentria is a patient-centric biotech company focused on novel biologics and biosimilars. Our first program is XT MAB 16, a monoclonal antibody for sarcoidosis. XT MAB 16 has received Orphan Drug Designation and is currently in a Phase 1 study.
The Manager/Senior Manager, Business Operations is responsible for the timely preparation, negotiation, and administration of clinical trial vendor contracts and accruals to ensure cost effective and accurate contracting services between the Company, its vendors and HCP's. The Manager/Senior Manager, Business Operations will partner with Clinical Operations, Legal, and Finance departments, as well as additional internal/external parties to identify contract needs, budgets, and other variables as needed.
No direct reports associated at this time.
To perform this job successfully, an individual must be able to perform each essential duty satisfactorily. The requirements listed below are representative of the knowledge, skill, and/or ability required. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.
Bachelor's degree and at least 4 years of relevant experience in the biotech, device, or pharmaceutical industry.
Equal Opportunity Employer Minorities/Women/Veterans/Disabled.
Microsoft Word, PowerPoint and Excel. Technical software skills and experience, including ERP systems, Business Intelligence Tools, and experience optimizing data analytics to enact business decisions.
While performing the duties of this Job, the employee is frequently required to stand; walk; sit and talk or hear. The employee must occasionally lift and/or move up to 20 pounds.
This is a remote position.
Headquartered in Chicago, the company is dedicated to R&D, clinical science, manufacturing, and commercialization while striving to treat the clinical and social disease burdens while fostering sustainable growth. Xentria, whose name stems from the word “centrality” was founded in 2020 and is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of cost-effective and efficacious treatments to address critical unmet needs for patients suffering from rare, immunologic, metabolic, and musculoskeletal diseases, as well as oncology.